Centre-independent detection of Non-small Cell Lung Cancer (NSCLC) by means of classification with receiver operating characteristic (ROC)-based data transformation

Anticancer Research

Volumn 30, Issue 5, 2010, Pages 1661-1665

  Norman, Bitterlich ^a   Thomas, Muley ^b   Joachim, Schneider ^c  

^a Medizin und Service GmbH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

CEA; CYFRA 21 1; Lung cancer; Marker panel; ROC curves

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT;

ADULT; BENIGN TUMOR; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CONFERENCE PAPER; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77954594723     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Schneider J, Bitterlich N, Velcovsky HG, Morr H, Katz N and Eigenbrodt E: Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol 7: 145-151, 2002.
2. Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N and Eigenbrodt E: Fuzzy logic-based tumor marker-profiles, including a new marker Tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients. Anticancer Res 23: 899-906, 2003. (Pubitemid 36750892)
3. Plebani M, Basso D, Navaglia F, De Paoli M, Tommasini A and Cipriani A: Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer 72: 170-173, 1995.
4. Unio Internationalis Contra Cancrum (UICC): TNM/L-Klassifikation maligner Tumoren. 5. Aufl. Deutsche Übersetzung (Hrsg.: Witteind Ch, Wagner G). Springer, Berlin, New York, 1997.
5. Bitterlich N and Schneider J: Decision guarantee in tumour marker analysis: a cut-off independent assessment. Anticancer Res 27: 1933-1940, 2007.
6. Schneider J: Tumor markers in detection of lung cancer. Advances Clin Chem 42: 1-41, 2006. (Pubitemid 44302105)
7. Ebert W and Muley T: Tumor-Marker - Bedeutung für Diagnostik und Verlaufskontrolle. In: Drings, Dienemann, Wannenmacher (eds.). Management des Lungenkarzinoms. Springer Verlag Berlin Heidelberg New York pp. 135-146, 2003.
8. Lombardi C, Tassi GF, Pizzicolo G and Donato F: Clinical significance of a multiple biomarker assay in patients with lung cancer. A study with logistic regression analysis. Chest 97: 639-644, 1990.
9. Kakari S, Stringou E, Toumbis M, Ferderigos AS, Poulaki E, Chondros K, Dema A, Kotsovoulou V and Pavlidis N: Five tumor markers in lung cancer: significance of total and "lipid"-bound sialic acid. Anticancer Res 11: 2107-2110, 1991.
10. Moro D, Villemain D, Vuillez JP, Delord CA and Brambilla C: CEA, CYFRA 21-1 and SCC in non-small cell lung cancer. Lung Cancer 13: 169-176, 1995.
11. Giovanella L, Ceriani L, Bandera M, Rimoldi R, Beghe B and Roncari G: Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21-1) immunoradiometric assay in non-small cell lung cancer evaluation. Q J Nucl Med 39: 285-289, 1995.
12. Koga H, Eguchi K, Shinkai T, Tamura T, Ohe Y, Oshita F, Saijo N, Kondo H, Oki K and Okura H: Preliminary evaluation of the new tumour marker CYFRA 21-1 in lung cancer patients. Jpn J Clin Oncol 24: 263-268, 1996.
13. Kohno N, Hirasawa Y, Kondo K, Fujioka S, Fujino S, Abe M, Yokoyama A, Hiwada K, Watanabe K and Nishimura J: Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma. Cancer Detect Prev 21: 124-128, 1997. (Pubitemid 27176875)
14. Bitterlich N and Schneider J: Cut-off-independent tumour marker evaluation using roc approximation. Anticancer Res 27: 4305-4310, 2007.